USPTO Examiner ZAHORIK AMANDA MARY - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18933499COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18933567COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18933750COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18933645COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18889137COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024February 2025Allow510YesNo
18807591COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSIONAugust 2024November 2024Allow301NoNo
18586689COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOFFebruary 2024January 2025Allow1110NoNo
18393408miRNA Switches for RNA-Triggered Control of RNA InterferenceDecember 2023March 2025Allow1530YesNo
18518177COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDNovember 2023February 2025Allow1531YesNo
18504827MICROORGANISMS AND USES THEREOFNovember 2023January 2025Abandon1411NoNo
18362675Compositions and Methods for Kallikrein (KLKB1) Gene EditingJuly 2023May 2025Abandon2231YesNo
18343014RNA AND DNA ANALYSIS USING ENGINEERED SURFACESJune 2023December 2024Allow1821YesNo
18144276COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOFMay 2023June 2025Allow2511NoNo
18040302COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSIONFebruary 2023June 2025Allow2811NoNo
17679977CODON-OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING AN AP-1 TRANSCRIPTION FACTORFebruary 2022November 2024Allow3321YesNo
17675229METAL ION-START DNA POLYMERASE SWITCH AND ISOTHERMAL POLYMERASE AMPLIFICATION METHOD USING THE SAMEFebruary 2022August 2024Allow3020YesNo
17583594Reporting Construct with Synaptobrevin Based MoietyJanuary 2022December 2024Allow3520NoNo
17582594SOLUTE CARRIER FAMILY 46 MEMBER 3 (SLC46A3) AS MARKER FOR LIPID-BASED NANOPARTICLE CANCER THERAPY AND DIAGNOSTICSJanuary 2022October 2024Allow3221YesNo
17604880p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASEOctober 2021May 2025Abandon4301NoNo
17593826RNAI MOLECULESeptember 2021April 2025Abandon4301NoNo
17441905COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERSSeptember 2021May 2025Abandon4301NoNo
17441620METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSENSeptember 2021April 2025Abandon4310NoNo
17440139RSK INHIBITORS IN THE TREATMENT OF VIRUS DISEASESSeptember 2021April 2025Abandon4301NoNo
17421277A METHOD OF TREATING CYSTIC FIBROSISJuly 2021May 2025Abandon4610NoNo
17420808TREATMENT OF FATTY LIVER DISEASEJuly 2021February 2025Abandon4401NoNo
17312740CONTROL OF INSECT INFESTATIONJune 2021November 2024Abandon4101NoNo
17311175ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9June 2021October 2024Abandon4001NoNo
17299355Cyclic Di-Nucleotide Compounds as STING AgonistsJune 2021March 2025Abandon4501NoNo
17296163NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELLMay 2021November 2024Abandon4201NoNo
17290582NEW THERAPYApril 2021October 2024Abandon4110NoNo
17245443ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1April 2021September 2024Abandon4101NoNo
17282340OLIGONUCLEOTIDE MEDIATED NO-GO DECAYApril 2021October 2024Abandon4310NoNo
17204008COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USEMarch 2021September 2024Abandon4201NoNo
17275132L-OLIGONUCLEOTIDE INHIBITORS OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2)March 2021June 2025Abandon5111NoNo
17196531RNAI INDUCED C9ORF72 SUPPRESSION FOR THE TREATMENT OF ALS/FTDMarch 2021October 2024Abandon4411NoNo
17271549SYSTEMS AND METHODS RELATED TO OLIGONUCLEOTIDE BUFFERSFebruary 2021June 2025Abandon5221NoNo
17269488FACTOR IX ENCODING NUCLEOTIDESFebruary 2021September 2024Allow4320NoNo
16973908COMPLEX FOR THE DELIVERY OF CAS9 PROTEINS AND GUIDE RNA TO CELLSDecember 2020June 2025Abandon5401NoNo
17052508REVERSE TRANSCRIPTASE SEQUENCE OF MARINE BACTERIOPHAGE AND USE THEREOFNovember 2020June 2024Abandon4410NoNo
16982977Immortalization of Splenic and Peripheral Blood Macrophages Using a Multi-Cistronic V-RAF/V-MYC LentivirusSeptember 2020March 2025Allow5421YesNo
16901514BACTERIAL QUANTITATIVE TRAIT-LOCUS MAPPINGJune 2020March 2025Allow5721YesNo
16760868CHEMICALLY-MODIFIED GUIDE RNAS TO IMPROVE CRISPR-CAS PROTEIN SPECIFICITYApril 2020May 2025Abandon6031NoNo
16781891ALGORITHMS FOR DISEASE DIAGNOSTICSFebruary 2020May 2025Abandon6011NoNo
16748267Method for Fragmenting Genomic DNA Using CAS9January 2020January 2025Abandon6020NoNo
16560685Increasing Cellular Lipid Production by Increasing the Activity of Diacylglycerol Acyltransferase and Decreasing the Activity of Triacylglycerol LipaseSeptember 2019April 2025Abandon6020NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner ZAHORIK, AMANDA MARY - Prosecution Strategy Guide

Executive Summary

Examiner ZAHORIK, AMANDA MARY works in Art Unit 1636 and has examined 38 patent applications in our dataset. With an allowance rate of 31.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner ZAHORIK, AMANDA MARY's allowance rate of 31.6% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ZAHORIK, AMANDA MARY receive 1.18 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ZAHORIK, AMANDA MARY is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +75.1% benefit to allowance rate for applications examined by ZAHORIK, AMANDA MARY. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 41.7% of applications are subsequently allowed. This success rate is in the 92% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Petition Practice

When applicants file petitions regarding this examiner's actions, 16.7% are granted (fully or in part). This grant rate is in the 8% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.